X4 Pharmaceuticals (XFOR)
(Real Time Quote from BATS)
$0.69 USD
-0.01 (-1.72%)
Updated Jul 15, 2024 10:46 AM ET
NA Value
NA Growth NA Momentum NA VGMX4 Pharmaceuticals (XFOR) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$4.12 | $5.50 | $1.00 | 488.57% |
Price Target
Based on short-term price targets offered by seven analysts, the average price target for X4 Pharmaceuticals comes to $4.12. The forecasts range from a low of $1.00 to a high of $5.50. The average price target represents an increase of 488.57% from the last closing price of $0.70.
Analyst Price Targets (7 )
Broker Rating
X4 Pharmaceuticals currently has an average brokerage recommendation (ABR) of 1.33 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by six brokerage firms. The current ABR compares to an ABR of 1.33 a month ago based on six recommendations.
Of the six recommendations deriving the current ABR, five are Strong Buy, representing 83.33% of all recommendations. A month ago, Strong Buy represented 83.33%.
Broker Rating Breakdown
![Broker Rating Visualization](https://widget3.zacks.com/images/charts/bar/brokerage/bar/XFOR.png)
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 5 | 5 | 5 | 5 | 5 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 1 | 1 | 1 | 1 | 1 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.33 | 1.33 | 1.33 | 1.33 | 1.33 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
6/28/2024 | H.C. Wainwright & Co. | Swayampakula Ramakanth | Strong Buy | Strong Buy |
5/31/2024 | Cantor Fitzgerald & Co | Kristen Kluska | Strong Buy | Strong Buy |
4/29/2024 | Brookline Capital Markets | Leah R Cann | Strong Buy | Strong Buy |
3/1/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
12/12/2023 | B. Riley Securities | Kalpit Patel | Strong Buy | Hold |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.33 |
ABR (Last week) | 1.33 |
# of Recs in ABR | 6 |
Average Target Price | $4.12 |
LT Growth Rate | NA |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 75 of 252 |
Current Quarter EPS Est: | -0.05 |